Citations

Showing 10 of 108119 citations.

Glomerular Function and Urinary Biomarker Changes between Vancomycin and Vancomycin plus Piperacillin-Tazobactam in a Translational Rat Model
Chang, Jack , Pais, Gwendolyn, Valdez, Kimberly, Marianski, Sylwia, Frazee, Erin N. , Scheetz, Marc H. , Pais, Gwendolyn M , Frazee, Erin N , Scheetz, Marc H

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 10, 2022 | Volume: 66 | Issue: 3 | Pages: No page available

10.1128/aac.02132-21 | PMID 35007142 Get It

Clinical studies have reported additive nephrotoxicity associated with the combination of vancomycin (VAN) and piperacillin-tazobactam (TZP). This study assessed differences in glomerular filtration rate (GFR) and urinary biomarkers between rats receiving VAN and those receiving VAN + TZP.
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis
Soh, Kah Teong , Came, Neil , Otteson, Gregory E., Olteanu, Horatiu , Natoni, Alessandro , Lagoo, Anand S., Theakston, Edward, Óskarsson, Jón Þórir , Gorniak, Malgorzata , Grigoriadis, George, Arroz, Maria , Fletcher, Matthew , Ludwig, Peter S., Tembhare, Prashant , Matuzevičienė, Rėda , Radzevičius, Mantas , Kay, Sigi, Chen, Weina , Cabrita, Carina, Wallace, Paul K. , Olteanu, Horatiu , Tembhare, Prashant , Chen, Weina , Jevremović, Dragan , Shi, Min , Fletcher, Matthew, Lin, Pei , Ludwig, Peter

Mayo Clinic

Cytometry Part B: Clinical Cytometry | January 10, 2022 | Volume: 102 | Issue: 2 | Pages: 88-106

10.1002/cyto.b.22053 | PMID 35005838 Get It

AbstractBackgroundMultiple myeloma (MM) measurable residual disease (MRD) evaluated by flow cytometry is a surrogate for progression‐free and overall survival in clinical trials. However, analysis and reporting between centers lack uniformity. We designed and evaluated a consensus protocol for MM MRD analysis to reduce inter‐laboratory variation in MM MRD reporting.MethodsSeventeen participants from 13 countries performed blinded analysis of the same eight de‐identified flow cytometry files from patients with/without MRD using their own method (Stage 1). A consensus gating protocol was then designed following survey and discussions, and the data re‐analyzed for MRD and other bone marrow cells (Stage 2). Inter‐laboratory variation using the consensus strategy was reassessed for another 10 cases and compared with earlier results (Stage 3).ResultsIn Stage 1, participants agreed on MRD+/MRD− status 89% and 68% of the time respectively. Inter‐observer variation was high for total numbers of analyzed cells, total and normal plasma cells (PCs), limit of detection, lower limit of quantification, and enumeration of cell populations that determine sample adequacy. The identification of abnormal PCs remained relatively consistent. By consensus method, average agreement on MRD− status improved to 74%. Better consistency enumerating all parameters among operators resulted in near‐unanimous agreement on sample adequacy.ConclusionUniform flow cytometry data analysis substantially reduced inter‐laboratory variation in reporting multiple components of the MM MRD assay. Adoption of a harmonized approach would meet an important need for conformity in reporting MM MRD for clinical trials, and wider acceptance of MM MRD as a surrogate clinical endpoint.
Acute-on-Chronic Liver Failure Clinical Guidelines
Bajaj, Jasmohan S. , O’Leary, Jacqueline G. , Long, Millie D. , Wong, Robert J. , Kamath, Patrick S. , Wong, Robert J , Lai, Jennifer C. , Wong, Florence

Mayo Clinic

American Journal of Gastroenterology | January 10, 2022 | Volume: 117 | Issue: 2 | Pages: 225-252

10.14309/ajg.0000000000001595 | PMID 35006099 Get It

In patients with cirrhosis and chronic liver disease, acute-on-chronic liver failure is emerging as a major cause of mortality. These guidelines indicate the preferred approach to the management of patients with acute-on-chronic liver failure and represent the official practice recommendations of the American College of Gastroenterology. The scientific evidence for these guidelines was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation process. In instances where the evidence was not appropriate for Grading of Recommendations, Assessment, Development, and Evaluation, but there was consensus of significant clinical merit, key concept statements were developed using expert consensus. These guidelines are meant to be broadly applicable and should be viewed as the preferred, but not only, approach to clinical scenarios.
Imaging Markers of Vascular Brain Health: Quantification, Clinical Implications, and Future Directions
Vemuri, Prashanthi , Decarli, Charles, Duering, Marco , DeCarli, Charles , DeCarli, Charles , Vemuri, Prashanthi , Duering, Marco

Mayo Clinic

Stroke | January 10, 2022 | Volume: 53 | Issue: 2 | Pages: 416-426

10.1161/strokeaha.120.032611 | PMID 35000423 Get It

Cerebrovascular disease (CVD) manifests through a broad spectrum of mechanisms that negatively impact brain and cognitive health. Oftentimes, CVD changes (excluding acute stroke) are insufficiently considered in aging and dementia studies which can lead to an incomplete picture of the etiologies contributing to the burden of cognitive impairment. Our goal with this focused review is 3-fold. First, we provide a research update on the current magnetic resonance imaging methods that can measure CVD lesions as well as early CVD-related brain injury specifically related to small vessel disease. Second, we discuss the clinical implications and relevance of these CVD imaging markers for cognitive decline, incident dementia, and disease progression in Alzheimer disease, and Alzheimer-related dementias. Finally, we present our perspective on the outlook and challenges that remain in the field. With the increased research interest in this area, we believe that reliable CVD imaging biomarkers for aging and dementia studies are on the horizon.
BRCA1 / BRCA2 mutation spectrum analysis in South Asia: a systematic review
Kharel, Sanjeev , Shrestha, Suraj , Yadav, Siddhartha , Shakya, Prafulla , Baidya, Sujita, Hirachan, Suzita, Yadav, Siddhartha

Mayo Clinic

Journal of International Medical Research | January 10, 2022 | Volume: 50 | Issue: 1 | Pages: No page available

10.1177/03000605211070757 | PMID 35000471 Get It

Objective Breast cancer (BC) is the most common form of cancer among Asian females. Mutations in the BRCA1/ BRCA2 genes are often observed in BC cases and largely increase the lifetime risk of having BC. Because of the paucity of high-quality data on the molecular spectrum of BRCA mutations in South Asian populations, we aimed to explore these mutations among South Asian countries. Methods A systematic literature search was performed for the BRCA1 and BRCA2 gene mutation spectrum using electronic databases such as PubMed, EMBASE, and Google Scholar. Twenty studies were selected based on specific inclusion and exclusion criteria. Results The 185delAG (c.68_69del) mutation in exon 2 of BRCA1 was the most common recurrent mutation and founder mutation found. Various intronic variants, variants of unknown significance, large genomic rearrangements, and polymorphisms were also described in some studies. Conclusions The South Asian population has a wide variety of genetic mutations of BRCA1 and BRCA2 that differ according to countries and ethnicities. A stronger knowledge of various population-specific mutations in these cancer susceptibility genes can help provide efficient strategies for genetic testing.
Clinicodemographic Predictors of Tracheotomy Tube Size and Decannulation
Panuganti, Bharat , Pang, John Henry , Francis, David O. , Klebaner, Dasha, Asturias, Alicia , Alattar, Ali , Wood, Samuel , Terry, M. C. , Bryson, Paul C. , Tipton, Courtney B. , Zhao, Elise E. , Maria, Chloe Santa , Sung, C. Kwang , Lao, Wilson P. , Thompson, Jordan M. , Crawley, Brianna K. , Rosen, Sarah P. , Berezovsky, Anna , Kupfer, Robbi A. , Hennesy, Theresa B. , Joseph, Ian T. , Sarhadi, Kamron, Kuhn, Maggie A. , Abdel‐Aty, Yassmeen , Kennedy, Maeve M. , Weissbrod, Philip A. , Sung, C K , Weissbrod, Philip A , Pang, John, Terry, Morgan, O'Rourke, Ashli , Grimm, David R. , Clary, Matthew S. , Lott, David G.

Mayo Clinic

Annals of Surgery | January 10, 2022 | Volume: 277 | Issue: 5 | Pages: e1138-e1142

10.1097/sla.0000000000005356 | PMID 35001037 Get It

Objective: We aimed to discern clinico-demographic predictors of large (≥8) tracheostomy tube size placement, and, secondarily, to assess the effect of large tracheostomy tube size and other parameters on odds of decannulation before hospital discharge. Summary of Background Data: Factors determining choice of tracheostomy tube size are not well-characterized in the current literature, despite evidence linking large tracheostomy tube size with posttracheotomy tracheal stenosis. The effect of tracheostomy tube size on timing of decannulation is also unknown, an important consideration given reported associations between endotracheal tube size and probability of failed extubation. Methods: We collected information pertaining to patients who underwent tracheotomy at 1 of 10 U.S. health care institutions between 2010 and 2019. Tracheostomy tube size was dichotomized (≥8 and <8). Multivariable logistic regression models were fit to identify predictors of (1) large tracheostomy tube size, and (2) decannulation before hospital discharge. Results: The study included 5307 patients, including 2797 (52.7%) in the large tracheostomy cohort. Patient height (odds ratio [OR] = 1.060 per inch; 95% confidence interval [CI] 1.041–1.070) and obesity (1.37; 95% CI 1.1891.579) were associated with greater odds of large tracheostomy tube; otolaryngology performing the tracheotomy was associated with significantly lower odds of large tracheostomy tube (OR = 0.155; 95% CI 0.131–0.184). Large tracheostomy tube size (OR = 1.036; 95% CI 0.885–1.213) did not affect odds of decannulation. Conclusions: Obesity was linked with increased likelihood of large tracheostomy tube size, independent of patient height. Probability of decannulation before hospital discharge is influenced by multiple patient-centric factors, but not by size of tracheostomy tube.
Management Practices for Asparaginase-associated Coagulopathy: A Survey of Pediatric Oncologists
Greenmyer, Jacob R., Wyatt, Kirk D., Rodriguez, Vilmarie, Ashrani, Aneel A., Warad, Deepti, Greenmyer, Jacob R., Wyatt, Kirk D., Rodriguez, Vilmarie, Ashrani, Aneel A., Warad, Deepti

Mayo Clinic

Journal of Pediatric Hematology/Oncology | January 10, 2022 | Volume: 44 | Issue: 8 | Pages: e1023-e1028

10.1097/mph.0000000000002396 | PMID 35001056 Get It

Background: Coagulopathy and thrombosis are well-described complications of asparaginase therapy. However, treatment practices in pediatric hematology/oncology (PHO) patients vary widely as evidence-based guidelines for clinical management of these complications in this population are lacking. Objective: The objective of this study was to assess management practices of asparaginase-related coagulopathy by pediatric hematologist/oncologist attending physicians. Design/Method: Email survey sent to 2327 PHO physicians primarily practicing in the United States. Results: Two hundred eighty-five (12.2%) attending physicians completed the survey. Only 4.6% (n=13/285) routinely prescribe prophylactic anticoagulation during induction chemotherapy for leukemia. Slightly more than half (n=145/250, 50.9%) of all providers perform baseline coagulation studies. Most providers that were surveyed (n=185/285, 64.9%) only replete coagulant factors if the patient experiences bleeding or bruising. One hundred thirty (n=130/285, 45.6%) physicians replace low fibrinogen. The median fibrinogen replacement was 100 mg/dL (range: 40 to 200 mg/dL) with the median target of at least 100 mg/dL (range: 50 to 200 mg/dL). A minority of physicians (n=39/250, 13.7%) replace low antithrombin. The median antithrombin cutoff activity level was 60% (range: 40% to 100%) with a median target of 75% (range: 40% to 125%). Conclusions: There is a significant variation in PHO physician practices for monitoring and management of asparaginase-associated hemostatic derangements. Evidence-based guidelines have the potential to standardize practices.
Mimics and Pitfalls of Primary Ovarian Malignancy Imaging
Elsherif, Sherif , Agely, Ali , Gopireddy, Dheeraj Reddy , Ganeshan, Dhakshinamoorthy , Hew, Karina E. , Lall, Chandana , Elsherif, Sherif B , Sharma, Smita

Mayo Clinic

Tomography | January 9, 2022 | Volume: 8 | Issue: 1 | Pages: 100-119

10.3390/tomography8010009 | PMID 35076619 Get It

The complex anatomy and similarity of imaging features of various pathologies in the pelvis can make accurate radiology interpretation difficult. While prompt recognition of ovarian cancer remains essential, awareness of processes that mimic ovarian tumors can avoid potential misdiagnosis and unnecessary surgery. This article details the female pelvic anatomy and highlights relevant imaging features that mimic extra-ovarian tumors, to help the radiologists accurately build a differential diagnosis of a lesion occupying the adnexa.
Molecular Investigation of miRNA Biomarkers as Chemoresistance Regulators in Melanoma: A Protocol for Systematic Review and Meta-Analysis
Shaw, Peter , Tzou, Katherine S., Baxi, Siddhartha , Mani, Ravishankar Ram, Govind, Suresh Kumar , Sivanandy, Palanisamy , Rajagopal, Mogana, Samiappan, Suja , Jayaraj, Rama , Ram, M. Ravishankar , Ram, M Ravishankar , Sivanandy, Palanisamy , Rajagopal, Mogana , Jayaraj, Rama , Shaw, Peter , Raymond, Greg, Chandramoorthy, Harish C. , Krishnan, Sunil

Mayo Clinic

Genes | January 9, 2022 | Volume: 13 | Issue: 1 | Pages: 115

10.3390/genes13010115 | PMID 35052456 Get It

Introduction: Melanoma is a global disease that is predominant in Western countries. However, reliable data resources and comprehensive studies on the theragnostic efficiency of miRNAs in melanoma are scarce. Hence, a decisive study or comprehensive review is required to collate the evidence for profiling miRNAs as a theragnostic marker. This protocol details a comprehensive systematic review and meta-analysis on the impact of miRNAs on chemoresistance and their association with theragnosis in melanoma. Methods and analysis: The articles will be retrieved from online bibliographic databases, including Cochrane Review, EMBASE, MEDLINE, PubMed, Scopus, Science Direct, and Web of Science, with different permutations of ‘keywords’. To obtain full-text papers of relevant research, a stated search method will be used, along with selection criteria. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Protocols 2015 (PRISMA-P) standards were used to create this study protocol. The hazard ratio (HR) with a 95% confidence interval will be analyzed using Comprehensive Meta-Analysis (CMA) software 3.0. (CI). The pooled effect size will be calculated using a random or fixed-effects meta-analysis model. Cochran’s Q test and the I2 statistic will be used to determine heterogeneity. Egger’s bias indicator test, Orwin’s and the classic fail-safe N tests, the Begg and Mazumdar rank collection test, and Duval and Tweedie’s trim and fill calculation will all be used to determine publication bias. The overall standard deviation will be evaluated using Z-statistics. Subgroup analyses will be performed according to the melanoma participants’ clinicopathological and biological characteristics and methodological factors if sufficient studies and retrieved data are identified and available. The source of heterogeneity will be assessed using a meta-regression analysis. A pairwise matrix could be developed using either a pairwise correlation or expression associations of miRNA with patients’ survival for the same studies.
Generation of Hydrogen Peroxide and Downstream Protein Kinase D1 Signaling Is a Common Feature of Inducers of Pancreatic Acinar-to-Ductal Metaplasia
Döppler, Heike, Liou, Geou‐Yarh , Störz, Peter , Döppler, Heike R, Liou, Geou-Yarh

Mayo Clinic

Antioxidants | January 9, 2022 | Volume: 11 | Issue: 1 | Pages: 137

10.3390/antiox11010137 | PMID 35052641 Get It

Pancreatic acinar-to-ductal metaplasia (ADM) is a reversible process that occurs after pancreatic injury, but becomes permanent and leads to pancreatic lesions in the presence of an oncogenic mutation in KRAS,. While inflammatory macrophage-secreted chemokines, growth factors that activate epidermal growth factor receptor (EGFR) and oncogenic KRAS have been implicated in the induction of ADM, it is currently unclear whether a common underlying signaling mechanism exists that drives this process. In this study, we show that different inducers of ADM increase levels of hydrogen peroxide, most likely generated at the mitochondria, and upregulate the expression of Protein Kinase D1 (PKD1), a kinase that can be activated by hydrogen peroxide. PKD1 expression in acinar cells affects their survival and mediates ADM, which is in part due to the PKD1 target NF-κB. Overall, our data implicate ROS-PKD1 signaling as a common feature of different inducers of pancreatic ADM.